
Abass Alavi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3565093/publications.pdf Version: 2024-02-01



Δρλςς Διλλη

#	Article	IF	CITATIONS
1	18F-NaF and 18F-FDG as molecular probes in the evaluation of atherosclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2190-2200.	6.4	97
2	A recovery coefficient method for partial volume correction of PET images. Annals of Nuclear Medicine, 2009, 23, 341-348.	2.2	89
3	A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial). Journal of Investigative Dermatology, 2020, 140, 85-93.e2.	0.7	83
4	An update on the role of PET/CT and PET/MRI in ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1079-1091.	6.4	82
5	Evolving Role of Molecular Imaging with 18F-Sodium Fluoride PET as a Biomarker for Calcium Metabolism. Current Osteoporosis Reports, 2016, 14, 115-125.	3.6	70
6	Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management. Nuclear Medicine Communications, 2008, 29, 367-373.	1.1	66
7	The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis. Journal of Nuclear Cardiology, 2017, 24, 19-28.	2.1	50
8	Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2009, 53, 9-19.	0.7	45
9	Dual-time-point Imaging and Delayed-time-point Fluorodeoxyglucose-PET/Computed Tomography Imaging in Various Clinical Settings. PET Clinics, 2016, 11, 65-84.	3.0	44
10	PET and PET–CT imaging of gynecological malignancies: present role and future promise. Expert Review of Anticancer Therapy, 2009, 9, 75-96.	2.4	35
11	Demonstration of Excessive Metabolic Activity of Thoracic and Abdominal Muscles on FDG-PET in Patients With Chronic Obstructive Pulmonary Disease. Clinical Nuclear Medicine, 2005, 30, 159-164.	1.3	33
12	What can be and what cannot be accomplished with PET to detect and characterize atherosclerotic plaques. Journal of Nuclear Cardiology, 2018, 25, 2012-2015.	2.1	30
13	Assessing the feasibility of NaF-PET/CT versus FDG-PET/CT to detect abdominal aortic calcification or inflammation in rheumatoid arthritis patients. Annals of Nuclear Medicine, 2020, 34, 424-431.	2.2	24
14	A critical review of radiotracers in the positron emission tomography imaging of traumatic brain injury: FDG, tau, and amyloid imaging in mild traumatic brain injury and chronic traumatic encephalopathy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 623-641.	6.4	23
15	The role of dual and multiple time point imaging of FDG uptake in both normal and disease states. Clinical and Translational Imaging, 2014, 2, 281-293.	2.1	21
16	Potential Roles of Total-Body PET/Computed Tomography in Pediatric Imaging. PET Clinics, 2020, 15, 271-279.	3.0	20
17	Effects of age and cardiovascular risk factors on (18)F-FDG PET/CT quantification of atherosclerosis in the aorta and peripheral arteries. Hellenic Journal of Nuclear Medicine, 2015, 18, 5-10.	0.3	18
18	Evolving Roles of Fluorodeoxyglucose and Sodium Fluoride in Assessment of Multiple Myeloma Patients. PET Clinics, 2019, 14, 341-352.	3.0	17

ABASS ALAVI

#	Article	IF	CITATIONS
19	Reinventing Molecular Imaging with Total-Body PET, Part II. PET Clinics, 2020, 15, 463-475.	3.0	17
20	Clinical Significance of Incidental Focal Versus Diffuse Thyroid Uptake on FDG-PET Imaging. PET Clinics, 2007, 2, 321-329.	3.0	16
21	Quantitative assessment of global hepatic glycolysis in patients with cirrhosis and normal controls using 18F-FDG-PET/CT: a pilot study. Annals of Nuclear Medicine, 2014, 28, 53-59.	2.2	16
22	Applications of PET Imaging in the Evaluation of Musculoskeletal Diseases Among the Geriatric Population. Seminars in Nuclear Medicine, 2018, 48, 525-534.	4.6	16
23	Quantitative thoracic aorta calcification assessment by 18F-NaF PET/CT and its correlation with atherosclerotic cardiovascular disorders and increasing age. European Radiology, 2021, 31, 785-794.	4.5	16
24	The role of positron emission tomography-computed tomography/magnetic resonance imaging in the management of sarcoidosis patients. Hellenic Journal of Nuclear Medicine, 2014, 17, 123-35.	0.3	16
25	An update on the unparalleled impact of FDG-PET imaging on the day-to-day practice of medicine with emphasis on management of infectious/inflammatory disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 18-27.	6.4	15
26	Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature. Hellenic Journal of Nuclear Medicine, 2015, 18, 11-8.	0.3	15
27	PET-based imaging to detect and characterize cardiovascular disorders: Unavoidable path for the foreseeable future. Journal of Nuclear Cardiology, 2018, 25, 203-207.	2.1	14
28	Futility of attempts to detect and quantify beta cells by PET imaging in the pancreas: why it is time to abandon the approach. Diabetologia, 2018, 61, 2512-2515.	6.3	14
29	Assessment of Total-Body Atherosclerosis by PET/Computed Tomography. PET Clinics, 2021, 16, 119-128.	3.0	14
30	Metastatic Seeding Attacks Bone Marrow, Not Bone. PET Clinics, 2019, 14, 135-144.	3.0	13
31	Applications of Fluorodeoxyglucose PET/Computed Tomography in the Assessment and Prediction of Radiation Therapy–related Complications. PET Clinics, 2015, 10, 555-571.	3.0	12
32	Normal patterns of regional brain F-FDG uptake in normal aging. Hellenic Journal of Nuclear Medicine, 2018, 21, 175-180.	0.3	12
33	On the use of [18F]DOPA as an imaging biomarker for transplanted islet mass. Annals of Nuclear Medicine, 2014, 28, 47-52.	2.2	11
34	Evolving Role of PET-Based Novel Quantitative Techniques in the Management of Hematological Malignancies. PET Clinics, 2019, 14, 331-340.	3.0	11
35	Evolving Role of PET/CT-MRI in Assessing Muscle Disorders. PET Clinics, 2019, 14, 71-79.	3.0	11
36	The effect of metal artefact reduction on CT-based attenuation correction for PET imaging in the vicinity of metallic hip implants: a phantom study. Annals of Nuclear Medicine, 2014, 28, 540-550.	2.2	9

ABASS ALAVI

#	Article	lF	CITATIONS
37	The Evolving Role of PET-Based Novel Quantitative Techniques in the Interventional Radiology Procedures of the Liver. PET Clinics, 2019, 14, 419-425.	3.0	9
38	Diagnosis and Monitoring of Osteoporosis with Total-Body 18F-Sodium Fluoride-PET/CT. PET Clinics, 2020, 15, 487-496.	3.0	9
39	CT-based tissue segmentation to assess knee joint inflammation and reactive bone formation assessed by F-FDG and F-NaF PET/CT: Effects of age and BMI. Hellenic Journal of Nuclear Medicine, 2018, 21, 102-107.	0.3	9
40	Clinical and Research Applications of Quantitative PET Imaging. PET Clinics, 2007, 2, 161-172.	3.0	8
41	An Update on the Role of Total-Body PET Imaging in the Evaluation of Atherosclerosis. PET Clinics, 2020, 15, 477-485.	3.0	8
42	Critical role of PET/CT-based novel quantitative techniques for assessing global disease activity in multiple myeloma and other hematological malignancies: why it is time to abandon reliance on examining focal lesions. European Radiology, 2021, 31, 149-151.	4.5	8
43	A Critical Review of PET Tracers Used for Brain Tumor Imaging. PET Clinics, 2021, 16, 219-231.	3.0	8
44	Imaging the Infected Heart. Science Translational Medicine, 2011, 3, 99fs3.	12.4	7
45	Comment on: "Tumor Aggressiveness and Patient Outcome in Cancer of the Pancreas Assessed by Dynamic 18F-FDG PET/CT― Journal of Nuclear Medicine, 2014, 55, 350-351.	5.0	7
46	Assessing the effects of body weight on subchondral bone formation with quantitative 18F-sodium fluoride PET. Annals of Nuclear Medicine, 2020, 34, 559-564.	2.2	7
47	Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. Hellenic Journal of Nuclear Medicine, 2014, 17, 78-84.	0.3	7
48	Patterns of 18F-FDG PET images in patients with uncomplicated total hip arthroplasty. Hellenic Journal of Nuclear Medicine, 2015, 18, 93-6.	0.3	7
49	PET imaging of <i>β</i> â€cell mass: is it feasible?. Diabetes/Metabolism Research and Reviews, 2012, 28, 601-602.	4.0	6
50	Carotid artery molecular calcification assessed by [18F]fluoride PET/CT: correlation with cardiovascular and thromboembolic risk factors. European Radiology, 2021, 31, 8050-8059.	4.5	6
51	Fluorine-18 DOPA-PET and PET/CT Imaging in Congenital Hyperinsulinism. PET Clinics, 2008, 3, 577-585.	3.0	5
52	Clinical Applications of Positron Emission Tomography in the Evaluation of Spine and Joint Disorders. PET Clinics, 2019, 14, 61-69.	3.0	5
53	An Update on the State of Tau Radiotracer Development: a Brief Review. Molecular Imaging and Biology, 2021, 23, 797-808.	2.6	5
54	Global temporal lobe asymmetry as a semi-quantitative imaging biomarker for temporal lobe epilepsy lateralization: A machine learning classification study. Hellenic Journal of Nuclear Medicine, 2018, 21, 95-101.	0.3	5

ABASS ALAVI

#	Article	IF	CITATIONS
55	Imaging for the diagnosis of thyroid cancer. Expert Opinion on Medical Diagnostics, 2009, 3, 237-249.	1.6	4
56	Emerging role of FDG-PET for optimal response assessment in infectious diseases and disorders. Expert Review of Anti-Infective Therapy, 2011, 9, 143-145.	4.4	4
57	Positron emission tomography. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 229-240.	1.8	4
58	Evolving Role of PET-Computed Tomography and PET-MR Imaging in Assessment of Musculoskeletal Disorders and Its Potential Revolutionary Impact on Day-to-Day Practice of Related Disciplines. PET Clinics, 2018, 13, xiii-xiv.	3.0	4
59	Suboptimal Sensitivity and Specificity of PET and Other Gross Imaging Techniques in Assessing Lymph Node Metastasis. Molecular Imaging and Biology, 2019, 21, 808-811.	2.6	4
60	Efficacy of F-FDG and F-NaF PET/CT imaging: A novel semi-quantitative assessment of the effects of age and obesity on hip joint inflammation and bone degeneration. Hellenic Journal of Nuclear Medicine, 2018, 21, 181-185.	0.3	4
61	Positron Emission Tomography Imaging and Hyperinsulinism. PET Clinics, 2007, 2, 377-383.	3.0	3
62	PET-Computed Tomography and PET-MR Imaging and TheirÂApplications in the Twenty-First Century. PET Clinics, 2019, 14, xv-xvii.	3.0	3
63	Evolving Role of PET in Pediatric Disorders. PET Clinics, 2020, 15, xv-xvii.	3.0	3
64	Utility of F-FDG PET/CT in pre-surgical risk stratification of patients with breast cancer. Hellenic Journal of Nuclear Medicine, 2019, 22, 165-171.	0.3	3
65	PET in Epilepsy and Other Seizure Disorders. PET Clinics, 2010, 5, 209-221.	3.0	2
66	Applications of Hybrid PET/Magnetic Resonance Imaging in Central Nervous System Disorders. PET Clinics, 2020, 15, 497-508.	3.0	2
67	Molecular imaging in management of colorectal metastases by the interventional oncologist. International Journal of Hyperthermia, 2022, 39, 675-681.	2.5	1
68	New Concepts for Assessing Global Organ Function and Disease Activity Based on Combined PET and Structural Imaging Techniques. PET Clinics, 2007, 2, 279-287.	3.0	0
69	PET and PET/CT Assessment of Gynecologic Malignancies: Beyond FDG. PET Clinics, 2010, 5, 477-482.	3.0	0
70	Achievements and beyond: Scientific trajectory of Professor Mohammad A. Rafi. BioImpacts, 2021, 11, 1-4.	1.5	0
71	Abass Alavi. A distinguished physician scientist and a pioneer in molecular imaging. Hellenic Journal of Nuclear Medicine, 2014, 17, 74-7.	0.3	0